Depressive symptoms and executive function in relation to survival in patients with glioblastoma

Introduction Depression and neurocognitive function, particularly executive functioning (EF), have been associated with overall survival (OS) in patients with glioblastoma (GBM). However, the combined effect of depressive symptoms and impaired EF upon OS has not been reported. Methods Patients with...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 2019-03, Vol.142 (1), p.183-191
Main Authors: Noll, Kyle R., Sullaway, Catherine M., Wefel, Jeffrey S.
Format: Article
Language:English
Subjects:
Adult
Aged
Brain cancer
Brain Neoplasms - complications
Brain Neoplasms - mortality
Brain Neoplasms - psychology
Clinical Study
Cognition
Cognitive ability
Depression - complications
Depression - mortality
Depression - psychology
Executive Function
Female
Glioblastoma
Glioblastoma - complications
Glioblastoma - mortality
Glioblastoma - psychology
Humans
Male
Medical prognosis
Medicine
Medicine & Public Health
Mental depression
Middle Aged
Mood
Neurology
Neuropsychological Tests
Oncology
Patients
Prognosis
Psychiatric Status Rating Scales
Quality of life
Quality of Life - psychology
Regression analysis
Survival
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Depression and neurocognitive function, particularly executive functioning (EF), have been associated with overall survival (OS) in patients with glioblastoma (GBM). However, the combined effect of depressive symptoms and impaired EF upon OS has not been reported. Methods Patients with GBM (N = 102) completed neuropsychological assessment postoperatively, including the Beck Depression Inventory-Second Edition (BDI-II) and the Trail Making Test Part B (TMTB). Median splits were used to determine cut-points denoting elevated depressive symptoms on the BDI-II and impaired EF on TMTB. Patients were stratified into four groups: low depressive symptoms/low EF impairment (− Dep/− Imp; N = 23), high depressive symptoms/low EF impairment (+ Dep/− Imp; N = 28), low depressive symptoms/high EF impairment (− Dep/+Imp; N = 28), and high depressive symptoms/high EF impairment (+ Dep/+Imp; N = 23). The Kaplan–Meier method, log-rank test, and Cox regression were used to examine differences in survival between groups. Results Relative to − Dep/− Imp patients (median OS = 22.8 months), median OS in all other patient groups was shorter (+ Dep/− Imp OS = 16.6; − Dep/+Imp OS = 14.8; +Dep/+Imp OS = 10.8; all p 
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-018-03081-z